FDA's Makary on Trump EO to Ease Access to Psychedelics

Summary

FDA Commissioner Dr. Marty Makary discusses the implications of President Trump's executive order aimed at accelerating research and access to psychedelic treatments. He details new funding, priority review vouchers, and regulatory pathways designed to cut approval times. The conversation focuses on the potential of compounds like ibogaine and MDMA for treating PTSD, while addressing safety concerns and past regulatory hurdles.

• President Trump signed an executive order to speed up psychedelic research and access.
• The FDA is allocating $50 million for psychedelic research and issuing priority review vouchers.
• Review times for breakthrough-designated therapies could drop from 6-10 months to 1-2 months.
• The order creates a pathway so psychedelics won't be treated as controlled substances in medical settings.
• Dr. Makary announced the first IND clearance for Noor Ibogaine for first-in-human trials.
• Applications for other psychedelics are expected this summer and may receive priority vouchers.
• The discussion highlights promising PTSD remission rates (30-40%) from preliminary data.
• Safety protocols and monitoring are emphasized due to known side effects of psychedelics.